Micafungin Accord

Micafungin, the active ingredient in Micafungin Accord, is a echinocandin antifungal presented as an injectable solution for intravenous use. It treats invasive candidiasis, esophageal candidiasis, intra‑abdominal Candida infections and is used for prophylaxis in hematopoietic stem‑cell transplant patients. GNH USA supplies Micafungin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres and pharmacies worldwide.

Micafungin is employed to manage serious Candida infections across several clinical settings.

- Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal infection of the esophagus. - Candida peritonitis and intra‑abdominal infections: treats intra‑abdominal Candida contamination. - Prophylaxis in hematopoietic stem‑cell transplantation: prevents Candida infection in high‑risk transplant recipients.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes after infusion. - Headache: mild to moderate intensity. - Rash: localized skin erythema. - Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects: - Hepatic failure: significant liver dysfunction. - Anaphylaxis: severe allergic reaction with airway compromise. - Infusion‑related reactions: hypotension or bronchospasm. - Neutropenia: marked reduction in neutrophil count. - Thrombocytopenia: low platelet levels. - Renal impairment: acute kidney injury in susceptible patients.

When using Micafungin, clinicians should consider several safety measures.

- Renal impairment: adjust therapy and monitor kidney function. - Hepatic impairment: assess liver enzymes before and during treatment. - Concomitant hepatotoxic drugs: avoid or closely monitor combined use. - Pregnancy: safety category unknown; weigh benefits against potential risks. - Pediatric use: limit to approved indications and monitor growth parameters. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Cyclosporine: may increase micafungin plasma levels, risking toxicity. - Rifampin: can markedly reduce micafungin exposure, compromising efficacy.

Moderate Interactions (Monitor Closely): - Azole antifungals (e.g., fluconazole): additive hepatotoxic potential, monitor liver tests. - Warfarin: possible alteration of INR, check coagulation parameters. - Immunosuppressants (e.g., tacrolimus): monitor drug levels for potential changes.